Fortfahren mit
Größe auswählen
| Ihnen/SKU | Verfügbarkeit | Preis |
|---|---|---|
125 mg | Warenkorb auf Verfügbarkeit prüfen | € 332,00 |
Über diesen Artikel
grade
pharmaceutical primary standard
agency
USP
API family
guanfacine
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
Cl.NC(=N)NC(=O)Cc1c(Cl)cccc1Cl
InChI
1S/C9H9Cl2N3O.ClH/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13;/h1-3H,4H2,(H4,12,13,14,15);1H
InChI key
DGFYECXYGUIODH-UHFFFAOYSA-N
Gene Information
human ... ADRA2A(150), ADRA2B(151), ADRA2C(152)
General description
For further information and support please go to the website of the issuing Pharmacopoeia.
Biochem/physiol Actions
Analysis Note
Other Notes
1 of 1
Dieser Artikel | |||
|---|---|---|---|
| manufacturer/tradename USP | manufacturer/tradename - | manufacturer/tradename - | manufacturer/tradename USP |
| grade pharmaceutical primary standard | grade - | grade certified reference material, pharmaceutical secondary standard | grade pharmaceutical primary standard |
| application(s) pharmaceutical (small molecule) | application(s) - | application(s) pharmaceutical (small molecule) | application(s) pharmaceutical (small molecule) |
| format neat | format - | format neat | format neat |
| API family guanfacine | API family - | API family guanfacine | API family clonidine |
| Gene Information human ... ADRA2A(150), ADRA2B(151), ADRA2C(152) | Gene Information human ... ADRA2A(150), ADRA2B(151), ADRA2C(152) | Gene Information human ... ADRA2A(150), ADRA2B(151), ADRA2C(152) | Gene Information human ... ADRA2A(150), ADRA2B(151), ADRA2C(152) |
Still not finding the right product?
Explore all of our products under Guanfacin -hydrochlorid
Lagerklasse
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

